Halozyme Therapeutics competitorsClear all

Agenus's top competitors include Blueprint Medicines.
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background
Agenus
Agenus
Agenus is a clinical-stage immuno-oncology company which focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer.
Blueprint Medicines
Blueprint Medicines
Blueprint Medicines discovers and develops highly selective kinase inhibitors for patients with genomically defined cancers.
Founding Date
Founding Date
1994
Founding Date
2011
Type
Type
Public
Type
Public
Tags
Locations
Locations
Lexington, US HQ
Cambridge, GB
Berkeley, US
New York, US
Locations
Cambridge, US HQ
Amsterdam, NL
Lugano, CH
Zug, CH
Cambridge, US
Employees
Employees
32812% increase
Employees
38376% increase
Valuation ($)
Valuation ($)
523.9 m
Valuation ($)
3.1 b
Twitter followers
Twitter followers
2.3 k
Twitter followers
2.6 k
Number of tweets (last 30 days)
Number of tweets (last 30 days)
11
Number of tweets (last 30 days)
14
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
8.8
Average likes per tweet (last 30 days)
6.4
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Alexa Website Rank
Alexa Website Rank
479547
Alexa Website Rank
365252
Employee Rating
Employee Rating
3.2
Employee Rating
4.2

Financial

Revenue (est.)
Revenue (est.)
$88.2m (FY, 2020)
Revenue (est.)
$793.7m (FY, 2020)
Cost of goods
Cost of goods
$2.3m (FY, 2020)
Cost of goods
$425k (FY, 2020)
Gross profit
Gross profit
$85.8m (FY, 2020)
Gross profit
$793.3m (FY, 2020)
Net income
Net income
($182.9m) (FY, 2020)
Net income
$313.9m (FY, 2020)

Funding

Total funding raised
Total funding raised
$ 171.1m
Total funding raised
$ 115m
For sources of this data, please see the company profile

View company profiles

Blueprint Medicines
HQ
Cambridge, US
Employees
383

Blueprint Medicines discovers and develops highly selective kinase inhibitors for patients with genomically defined cancers.

View company